Vivos Therapeutics has entered into securities purchase agreements with institutional investors for a registered direct offering of 1,363,812 common shares at $3.15 per share, expecting to raise approximately $4.3 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. serving as the exclusive placement agent.The company plans to use the net proceeds for working capital and general corporate purposes. No common stock purchase warrants were issued to investors, though the placement agent will receive warrants to purchase up to 95,467 shares at $3.9375 per share. The offering is expected to close on September 20, 2024, subject to customary closing conditions.Under the agreement terms, Vivos has agreed to certain restrictions on share issuance for 30 days following the closing and will not effect any Variable Rate Transactions for one year. The shares are being offered through an effective shelf registration statement previously filed with the SEC.

Vivos Therapeutics has entered into securities purchase agreements with institutional investors for a registered direct offering of 1,363,812 common shares at $3.15 per share, expecting to raise approximately $4.3 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. serving as the exclusive placement agent.The company plans to use the net proceeds for working capital and general corporate purposes. No common stock purchase warrants were issued to investors, though the placement agent will receive warrants to purchase up to 95,467 shares at $3.9375 per share. The offering is expected to close on September 20, 2024, subject to customary closing conditions.Under the agreement terms, Vivos has agreed to certain restrictions on share issuance for 30 days following the closing and will not effect any Variable Rate Transactions for one year. The shares are being offered through an effective shelf registration statement previously filed with the SEC.